| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/16/2010 | US7662392 Stromal-Derived Factor-1 (SDF), G-CSF (granulocyte-colony stimulating factor), stimulating vasculogenesis; improves cardiac function |
| 02/16/2010 | US7662380 ZAQ ligand-1 antibodies and uses thereof |
| 02/16/2010 | CA2452918C New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 02/16/2010 | CA2450922C Piperidines for use as orexin receptor antagonists |
| 02/16/2010 | CA2445329C 20-hydroxyeicosatetraenoic acid production inhibitors |
| 02/16/2010 | CA2442882C Sulphones which modulate the action of gamma-secretase |
| 02/16/2010 | CA2440037C Benzimidazole derivatives for modulating the rage receptor |
| 02/16/2010 | CA2429109C Anti-inflammatory agents |
| 02/16/2010 | CA2410399C 5-aminoalkylpyrazolo[4,3-d]pyrimidines |
| 02/16/2010 | CA2407043C Naphthamidine urokinase inhibitors |
| 02/16/2010 | CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 02/16/2010 | CA2385938C Cyclic amine compounds as ccr5 antagonists |
| 02/16/2010 | CA2346082C Tricyclic .delta.3-piperidines as pharmaceuticals |
| 02/16/2010 | CA2344435C Compositions for the treatment of male erectile dysfunction |
| 02/16/2010 | CA2308551C Phenanthroline derivatives |
| 02/16/2010 | CA2287387C Methods and compositions for destruction of selected proteins |
| 02/16/2010 | CA2223701C Fgf9 as a specific ligand for fgfr3 |
| 02/11/2010 | WO2010016590A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 02/11/2010 | WO2010016554A1 Cyclic amine compound |
| 02/11/2010 | WO2010016549A1 Tricyclic compound |
| 02/11/2010 | WO2010016490A1 Imidazopyridin-2-on derivative |
| 02/11/2010 | WO2010015701A1 Improved bacterial polysaccharide-polypeptide conjugate compositions |
| 02/11/2010 | WO2010015628A1 Pyrazolo [5,1-b] oxazole derivatives as crf1 antagonists |
| 02/11/2010 | US20100035976 Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog |
| 02/11/2010 | US20100035968 Mediated cellular delivery of lna oligonucleotides |
| 02/11/2010 | US20100035943 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors |
| 02/11/2010 | US20100035903 administering 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or salts, for the treatment of dermatitis, Crohn's disease, inflammatory bowel disease, transplant rejection, lupus, multiple sclerosis, arthritis, psoriasis, diabetes and autoimmune diseases |
| 02/11/2010 | US20100035891 Pharmaceutically Active Compounds |
| 02/11/2010 | US20100035885 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 02/11/2010 | US20100035874 Organic compounds |
| 02/11/2010 | US20100035842 Amino alcohol compounds or phosphonic acid derivatives thereof |
| 02/11/2010 | US20100035838 Cross-linked polysaccharide gels |
| 02/11/2010 | US20100035819 Method of promoting skin collagen production |
| 02/11/2010 | US20100035808 Methods and compositions for promoting organ development |
| 02/11/2010 | US20100034890 Combinations of formoterol and fluticasone propionate for asthma |
| 02/11/2010 | US20100034888 Granulate containing a pharmaceutically active substance and method for its manufacture |
| 02/11/2010 | US20100034862 Covalently grafted pharmaceutically active polymers |
| 02/11/2010 | US20100034861 Dispersions of nanoureas comprising biologically active compounds |
| 02/11/2010 | US20100034859 Method for making an implantable biocompatible material with mixed Pseudo-crystalline lattice and material obtainable by said method |
| 02/11/2010 | US20100034776 Replication-competent anti-cancer vectors |
| 02/11/2010 | US20100034743 Raman Characterization of Transplant Tissue |
| 02/11/2010 | CA2733176A1 Pyrazolo [5,1-b] oxazole derivatives as crf1 antagonists |
| 02/11/2010 | CA2732950A1 Imidazopyridin-2-one derivatives |
| 02/10/2010 | EP2151454A2 Platelet-derived growth factor D, DNA coding therefor, and uses thereof |
| 02/10/2010 | EP2151439A1 Nitrogenated aromatic 6-membered ring derivative, and pharmaceutical agent comprising the same |
| 02/10/2010 | EP2151438A1 Pharmaceutical containing ppar agonist |
| 02/10/2010 | EP2151244A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/10/2010 | EP2151236A1 G-protein-conjugated receptor agonist |
| 02/10/2010 | EP2150254A2 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| 02/10/2010 | EP1525191B1 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives |
| 02/10/2010 | EP1490365B1 Azaindoles as inhibitors of c-jun n-terminal kinases |
| 02/10/2010 | EP1411932B1 Substituted oxazolidinones for combinational therapy |
| 02/10/2010 | EP1404659B1 4-aryl quinols and analogs thereof as therapeutic agents |
| 02/10/2010 | EP1278546B1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents |
| 02/10/2010 | CN101643789A RNA interference mediating small RNA molecules |
| 02/10/2010 | CN101643732A A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 02/10/2010 | CN101643512A Novel immunoadhesin for the prevention of rhinovirus infection |
| 02/10/2010 | CN101643470A Alkyl ether derivatives or salts thereof |
| 02/10/2010 | CN101642459A Combination dosage form containing a cholesterol -lowering agent, an inhibitor of the renin-angiotensin, and aspirin |
| 02/10/2010 | CN100588649C Method for producing condensed imidazole compound, reformatsky reagent having stable form and production thereof |
| 02/10/2010 | CN100588647C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 02/09/2010 | US7659407 Pharmaceutical compounds |
| 02/09/2010 | US7659404 Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors |
| 02/09/2010 | US7659377 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
| 02/09/2010 | US7659375 Interleukin specific immunoglobulin for prevention and treatment of vision, autoimmune, inflammatory and diabetic disorders |
| 02/09/2010 | US7659373 Producing such EPO products characterized by a high proportion of N-acetyl-lactosamine units or/and tetraantennary branches in the carbohydrate structure |
| 02/09/2010 | US7659303 Reduce tumor necrosis factor; phosphodiesterase inhibitor; antiinflammatory agents; anticancer agents; antidepressants; skin diosrders |
| 02/09/2010 | US7659302 Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
| 02/09/2010 | US7659293 α-Amino-N-hydroxy-acetamide derivatives |
| 02/09/2010 | US7659282 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 02/09/2010 | US7659272 N-[phenyl or heteroaryl carbonoyl pyridyl] arylsulfonamides; antiinflammatory, antianaphylactic agents; transplant rejection, gastointestinal, respriatory system and skin disorders |
| 02/09/2010 | US7659269 Substituted indolealkanoic acids |
| 02/09/2010 | US7659267 2-(3-cyanophenyl)-4H-1,3-benzothiazin-4-one; cardiovascular, bone or joint diseases, infectious, inflammatory, kidney diseases; safe and good effects of cell death inhibition, Migration Inhibitory Factor (MIF) binding |
| 02/09/2010 | US7659263 (E)-3-[4-({1-[(11-cyclohexyl-8-methoxy-4,5-dihydro-6-oxa-1-thia-3b-azabenzo[e]cyclopenta[a]azulene-2-carbonyl)amino]cyclobutanecarbonyl}amino)phenyl]acrylic acid; RNA-dependent RNA polymerase inhibitory activity; hepatitis C |
| 02/09/2010 | US7659249 Membrane-permeable NFAT inhibitory peptide |
| 02/09/2010 | US7658939 Inert core, first layer comprising naltrexone, nalmefene or salts; and second hydrophobic layer; pain treatment |
| 02/09/2010 | CA2625906C Lazaroids-based compositions and methods for preventing adhesion formation using the same |
| 02/09/2010 | CA2483597C New pharmaceutical compositions containing flibanserin polymorph a |
| 02/09/2010 | CA2471265C Pyrimidotriazines as phosphatase inhibitors |
| 02/09/2010 | CA2451562C Piperazine compound |
| 02/09/2010 | CA2451240C Cyclic diamine compound with 6 membered ring groups |
| 02/09/2010 | CA2439593C Heterocyclic compounds for aging-related and diabetic vascular complications |
| 02/09/2010 | CA2431079C Method and composition for the treatment of diabetic neuropathy |
| 02/09/2010 | CA2430273C Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them |
| 02/09/2010 | CA2422496C Disinfectant comprising an amine and an alkanolamine |
| 02/09/2010 | CA2413061C Serine protease inhibitors |
| 02/09/2010 | CA2410647C Substituted phenylpropanoic acid derivatives |
| 02/09/2010 | CA2389688C A method of microencapsulation |
| 02/09/2010 | CA2386297C Bicyclic amino acids as pharmaceutical agents |
| 02/09/2010 | CA2378976C Method of controlling body temperature while reducing shivering |
| 02/09/2010 | CA2354762C Novel therapeutic application of low molecular weight heparin |
| 02/09/2010 | CA2349875C Dna encoding a growth factor specific for epithelial cells |
| 02/09/2010 | CA2330925C Pharmaceutical formulations for igf/igfbp |
| 02/09/2010 | CA2315646C Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| 02/09/2010 | CA2308274C Methods for modulating macrophage proliferation using polyamine analogs |
| 02/09/2010 | CA2293806C Alpha 1-antitrypsin preparation as well as a method for producing the same |
| 02/09/2010 | CA2291065C Raf kinase inhibitors |
| 02/09/2010 | CA2274201C Di-or triaza-spiro[4,5]decane derivatives |
| 02/09/2010 | CA2201863C Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors |
| 02/09/2010 | CA2192092C Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors |